End-of-day quote
Shanghai S.E.
06:00:00 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
5.24
CNY
|
-0.38%
|
|
-5.07%
|
-41.71%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,400
|
5,820
|
3,393
|
-
|
-
|
Enterprise Value (EV)
1 |
9,400
|
5,820
|
3,393
|
3,393
|
3,393
|
P/E ratio
|
230
x
|
-45.2
x
|
-29.1
x
|
296
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
32.3
x
|
27.3
x
|
9.95
x
|
7.55
x
|
9.14
x
|
EV / Revenue
|
32.3
x
|
27.3
x
|
9.95
x
|
7.55
x
|
9.14
x
|
EV / EBITDA
|
143
x
|
-48.7
x
|
74.8
x
|
38.3
x
|
-
|
EV / FCF
|
-
|
-9.14
x
|
-15.9
x
|
-21.2
x
|
106
x
|
FCF Yield
|
-
|
-10.9%
|
-6.28%
|
-4.72%
|
0.94%
|
Price to Book
|
4.33
x
|
2.82
x
|
1.75
x
|
1.33
x
|
-
|
Nbr of stocks (in thousands)
|
641,146
|
647,433
|
647,433
|
-
|
-
|
Reference price
2 |
14.66
|
8.990
|
5.240
|
5.240
|
5.240
|
Announcement Date
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
291.3
|
213
|
340.9
|
449.2
|
371
|
EBITDA
1 |
-
|
65.77
|
-119.4
|
45.36
|
88.64
|
-
|
EBIT
1 |
-
|
41.71
|
-156.1
|
-123
|
13
|
-
|
Operating Margin
|
-
|
14.32%
|
-73.26%
|
-36.09%
|
2.89%
|
-
|
Earnings before Tax (EBT)
1 |
-
|
41.62
|
-156.2
|
-123
|
5.5
|
-
|
Net income
1 |
54.26
|
39.03
|
-128
|
-116
|
10.17
|
-
|
Net margin
|
-
|
13.4%
|
-60.09%
|
-34.03%
|
2.26%
|
-
|
EPS
2 |
0.1077
|
0.0638
|
-0.1990
|
-0.1800
|
0.0177
|
-
|
Free Cash Flow
1 |
-
|
-
|
-637
|
-213
|
-160
|
32
|
FCF margin
|
-
|
-
|
-299.01%
|
-62.49%
|
-35.62%
|
8.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-637
|
-213
|
-160
|
32
|
ROE (net income / shareholders' equity)
|
-
|
2.12%
|
-6.06%
|
-0.58%
|
1.36%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
1.75%
|
-4.98%
|
-4.5%
|
-0.25%
|
-
|
Assets
1 |
-
|
2,233
|
2,573
|
2,578
|
-4,067
|
-
|
Book Value Per Share
2 |
-
|
3.390
|
3.190
|
3.000
|
3.930
|
-
|
Cash Flow per Share
2 |
-
|
0.0300
|
-0.1400
|
-0.1600
|
0.1200
|
-
|
Capex
1 |
-
|
484
|
547
|
103
|
67.5
|
38
|
Capex / Sales
|
-
|
166.29%
|
256.71%
|
30.22%
|
15.03%
|
10.24%
|
Announcement Date
|
3/2/22
|
2/23/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
5.24
CNY Average target price
8.2
CNY Spread / Average Target +56.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -41.71% | 468M | | +42.69% | 749B | | +38.72% | 605B | | -6.87% | 351B | | +18.74% | 328B | | +6.76% | 292B | | +18.90% | 248B | | -2.29% | 214B | | +11.25% | 216B | | +2.64% | 167B |
Other Pharmaceuticals
|